Lower Urinary Tract Disorders
Total Page:16
File Type:pdf, Size:1020Kb
37 Lower Urinary Tract Disorders Michael Perrotti Objectives 1. To discuss the evaluation and treatment options for men with benign prostatic hyperplasia and lower urinary tract symptoms (urinary frequency, nocturia, urgency, urinary retention). • Consider pertinent history and physical, diag- nostic tests 2. To outline the evaluation and treatment options for patients with urinary incontinence. 3. To describe the potential etiologies of hematuria. • Consider age, presence of pain, character of bleeding, trauma • Consider occult versus gross hematuria 4. To discuss the diagnostic modalities available for evaluation of hematuria including risks, indica- tions, and limitations. • Consider computed tomography (CT), cys- toscopy, intravenous pyelogram, ultrasound, cystourethrogram, and retrograde pyelography 5. To discuss the etiologies and diagnostic evalua- tion of a patient with dysuria. 6. To discuss the etiologies and workup of a patient with pneumaturia. Cases Case 1 A 67-year-old woman may have a history of stress incontinence fol- lowing the birth of her third child and reports a worsening at the time of menopause, but she seeks medical care at the present time because of inability to “hold my urine” 2 years after suffering a cerebral vas- cular accident. She has no other neurologic residua. 656 37. Lower Urinary Tract Disorders 657 Case 2 A 17-year-old boy is brought to the emergency department after sus- taining a bicycle accident. He is noted to have gross blood at the penile meatus. He has not voided since the time of his accident. Case 3 A 22-year-old college student complains of burning with urination. He has a clear urethral discharge and recently has engaged in unprotected intercourse. Introduction Lower urinary tract disorders are intended to include those complaints related to the function of voiding that prompt a patient to seek the care of a physician. Such complaints may be a result of a primary urinary tract etiology (i.e., urinary tract infection) or of a secondary urinary tract etiology (i.e., bladder hyperreflexia following cerebral vascular accident). Hence, a complete and accurate history and a complete and accurate physical examination remain of the utmost importance in the evaluation of such patients. This chapter discusses the presentation, workup, and treatment of common lower urinary tract disorders, including benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), urinary incontinence, hematuria, cystitis, dysuria, and pneumaturia. Benign Prostatic Hyperplasia (BPH) and Lower Urinary Tract Symptoms (LUTS) It is estimated that there are approximately 6 million patient visits annually among U.S. males for the evaluation of symptoms attribut- able to enlargement of the prostate gland. It is incumbent upon the evaluating physician to have a consistent approach to this disorder, to identify patients at increased risk of adverse event (i.e., acute urinary retention), and to initiate appropriate therapy in those patients in whom it is required. It also is important to detect disease states that can mimic the symptoms of BPH. The Agency for Health Care Policy and Research recommends that all males with lower urinary com- plaints be administered a Prostate Symptom Questionnaire (Table 37.1). This scoring system addresses six areas of voiding dysfunction that are scored from 0 (no symptoms) to 5 (severe symptoms), for a composite score ranging from 0 to 30. Differential Diagnosis It is important to rule out other etiologies of urinary symptoms in making the diagnosis of benign prostatic hyperplasia. The presence of prostate cancer must be ruled out since treatment of benign disease would be ineffective and would result in further disease 658 M. Perrotti Table 37.1. American Urologic Association Prostate Symptom Index. Symptom (each scored as 0–5) Scale Sense of incomplete emptying 0, not at all Frequency 1, less than 1 in 5 Intermittency 2, less than 50% of time Urgency 3, about half the time Straining 4, greater than 50% of time Nocturia 5, almost always progression. This can be accomplished with a well-performed digital rectal examination (DRE), a serum prostate-specific antigen (PSA) test, and reference to normal value ranges. It generally is recognized that a prostate biopsy is indicated in those men with either elevated serum PSA level (>4ng/mL) or a suspicious DRE finding before embarking upon a BPH treatment regimen (see Algorithm 37.1, Table 37.2). Irritative symptoms such as urinary frequency may be due to under- lying urinary tract infection, bladder malignancy, primary bladder disorder (i.e., radiation cystitis), or neurologic disease such as history of cerebral vascular accident, multiple sclerosis, or Parkinson’s disease (Table 37.3). Similarly, poor bladder emptying may be seen in primary neurologic disease and in the neuropathy associated with diabetes. In cases that are not diagnostically clear, urodynamic testing is performed to assess bladder function quantitatively. During this office procedure, the bladder is drained after voiding to measure postvoid residual, and then the bladder is filled at a determined rate and bladder pressure is Initial evaluation Hx, PE, DRE Urinalysis Serum PSA AUA-SI Refractory urine retention Abnormal DRE Hematuria Prostate Failed med management Elevated PSA Symptom Gross hematuria Index Bladder calculus Mild Mod/severe Surgical intervention R/O prostate cancer Renal US Watchful waiting Tx alternatives Urine cytology Cystoscopy Algorithm 37.1. Algorithm for the evaluation and treatment of benign prostate hyperplasia. AUA-SI, American Urologic Association Prostate Symptom Index; DRE, digital rectal exam; Hx, history; PE, physical examination; PSA, prostate-specific antigen; R/O, rule out; US, ultrasound. 37. Lower Urinary Tract Disorders 659 Table 37.2. Results of watchful waiting series for prostate cancer. Follow-up Overall Dz-specific CaP Level of Author n (years) mortality (%) mortality (%) progression (%) evidence Johanssona 223 10.2 56 8 34 III Whitmoreb 75 9.5 39 15 69 III Hanashc 179 15 55 45 NA III Georged 120 7 44 4 83 III Madsene 50 10 52 6 18 III a Johansson J-E, Adami H-O, Andersson S-O, et al. High 10-year survival rate in patients with early, untreated pros- tatic cancer. JAMA 1992;267:2191–2196. b Whitmore WF, Warner JA, Thompson IM. Expectant management of localized prostatic cancer. Cancer (Phila) 1991;67:1091–1096. c Hanash KA, Utz DC, Cook EN, et al. Carcinoma of the prostate: a 15-year follow-up. J Urol 1972;107:450–453. d George NJR. Natural history of localized prostatic cancer managed by conservative therapy alone. Lancet 1988;494–497. e Madsen PO, Graverson PH, Gasser TC, et al. Treatment of localized prostatic cancer: radical prostatectomy versus placebo: a 15-year follow-up. Scand J Urol Nephrol Suppl 1988;110:95–100. Source: Reprinted from Presti JC Jr. Urology. In: Norton JA, Bollinger RR, Chang AE, et al, eds. Surgery: Basic Science and Clinical Evidence. New York: Springer-Verlag, 2001, with permission. measured. While performing this study, record is made of the bladder’s response to filling (i.e., sensation, compliance, stability, capacity) and the peak strength of bladder pressure generation during voiding. The peak bladder voiding pressure is correlated with the electronically measured voiding urine flow measurement. Cases of mixed disease states pose a management challenge. A patient may have poor bladder contractility secondary to diabetic nephropathy aggravated by bladder obstruction secondary to BPH. In such patients, results of BPH management often are suboptimal. In men with Parkinson’s disease and bladder outlet obstruction secondary to BPH, transurethral resection of the prostate (TURP) is associated with a high rate of incontinence and is avoided, and maximal medical man- agement is utilized. Treatment It generally is recommended that a discussion of treatment options be initiated in those men with moderate (8 to 19) or severe (≥20) symptom scores (Table 37.4). Treatment may include surveillance alone, medical management, or surgical intervention, the gold stan- dard being electrosurgical TURP. After hearing a discussion of the potential risks and benefits of available therapies, most patients want medical management in an attempt to avoid a surgical procedure if possible. Medical Management Medical management consists primarily of a-receptor blockade or 5a- reductase inhibition (Table 37.5). Alpha-blocker agents (i.e., Cardura, Hytrin, Flomax) have been shown to decrease the tone of the a- innervated muscle of the prostatic stroma and bladder neck regions. These agents decrease the symptom score and improve urinary flow rates. As a result, the alpha-blockers are Food and Drug Administration 660 M. Perrotti Table 37.3. Urodynamic findings in selected neurologic disorders. Common urodynamic Disorder finding Suprapontine lesions Cerebral aneurysm DH Brain abscess DH Olivopontocerebellar degeneration DH Multiple system atrophy DH, DA, ISD Parkinson’s disease DH, DSD, ISD Senile dementia DH Cerebral palsy DH Cerebral vascular disease DH, DA (acute) Cerebellar ataxia DH Bilateral lesions of the putamen DH, DA Normal pressure hydrocephalus DH, DA Huntington’s chorea DH Hereditary ataxias DH Shy-Drager DA, ISD Spinal lesions Multiple sclerosis DH, DA, DSD Syringomyelia DH, DSD Herniated disk (cervical, thoracic) DH, DSD Herniated disk (lumbosacral) DA, DH Hereditary spastic paraparesis DH Tropical spastic paraparesis DH Myelomeningocele DA, DH, DSD, ISD Anterior spinal artery syndrome DH, DA (nl sensation) Sacral